Adage Capital Partners Gp, L.L.C. Immunovant, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $54.6 Billion
- Q3 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Immunovant, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 300,000 shares of IMVT stock, worth $8.25 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
300,000
Previous 420,000
28.57%
Holding current value
$8.25 Million
Previous $11.1 Million
25.57%
% of portfolio
0.02%
Previous 0.02%
Shares
10 transactions
Others Institutions Holding IMVT
# of Institutions
211Shares Held
66.9MCall Options Held
2.3MPut Options Held
631K-
Vanguard Group Inc Valley Forge, PA6.66MShares$183 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.92MShares$135 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.35MShares$120 Million4.41% of portfolio
-
Armistice Capital, LLC New York, NY3.55MShares$97.6 Million1.62% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.33MShares$91.6 Million0.06% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...